Severance Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Electrophysiological Dose-Response to Anterior Thalamic Deep Brain Stimulation in Drug-Resistant Focal Epilepsy

  NCT07912931· Yonsei University· Source

• Recruiting

  Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC

  NCT07933055· Phase 1/2· Txinno Bioscience Inc.· Source

• Recruiting

  Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA

  NCT07921888· Eun Hye Lee· Source

• Recruiting

  Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis

  NCT07901790· Yonsei University· Source

• Not yet recruiting

  Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation

  NCT07486739· Seoul National University Hospital· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

  NCT07154745· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

  NCT07629115· Innopeutics Corporation· Source

• Recruiting

  Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

  NCT07524101· Yonsei University· Source

• Recruiting

  A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

  NCT07481357· Phase 1· Dong-A ST Co., Ltd.· Source

• Recruiting

  Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

  NCT07371338· Phase 1· Innopeutics Corporation· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  AI-based Customized tDCS for Finger Motor Recovery After Subacute Stroke

  NCT07491029· NEUROPHET· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

  NCT07423117· Phase 1· IntoCell, Inc· Source

• Recruiting

  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

  NCT07010497· Phase 2· Asan Medical Center· Source

• Recruiting

  Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

  NCT07359105· Sin Gon Kim· Source

• Recruiting

  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  NCT07469683· Phase 2· Yonsei University· Source

• Recruiting

  Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

  NCT07449754· Phase 2· Hanmi Pharmaceutical Company Limited· Source

• Recruiting

  A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

  NCT07187401· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer

  NCT07853209· Phase 3· FutureChem· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease

  NCT07869238· Neumous Inc.· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  Dronedarone Rhythm Intervention for Early Atrial Fibrillation

  NCT07270848· Phase 4· Inha University Hospital· Source

• Recruiting

  Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  NCT06975787· Phase 1· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Enrolling by invitation

  The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer

  NCT07376980· Korea University Anam Hospital· Source

• Recruiting

  Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

  NCT07235007· Aichi Medical University· Source

• Not yet recruiting

  Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia

  NCT07247240· Phase 4· Asan Medical Center· Source

• Not yet recruiting

  Thickness Map-Guided vs. Empirical PV Isolation Using Pulsed Field Ablation for Paroxysmal AF

  NCT07068646· Yonsei University· Source

• Recruiting

  First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury

  NCT06922890· Phase 1/2· Yonsei University· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  NCT07049926· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Not yet recruiting

  Effect of Bilateral vs. Unilateral Alveolar Recruitment on Gas Exchange in Lung Resection

  NCT07044661· Yonsei University· Source

• Not yet recruiting

  A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

  NCT06885567· Phase 2· BeyondBio Inc.· Source

• Recruiting

  Streamlining Radioembolization for CCC and Metastatic Liver Cancer

  NCT07043387· Seoul National University Hospital· Source

• Recruiting

  Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

  NCT06984952· Seoul National University Hospital· Source

• Recruiting

  Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

  NCT06975410· Phase 1/2· Yuhan Corporation· Source

• Recruiting

  Streamlining Radioembolization for Small HCC

  NCT06979219· Seoul National University Hospital· Source

• Recruiting

  Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

  NCT06873763· Phase 1/2· STCube, Inc.· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

  NCT06962098· Phase 2· Aptabio Therapeutics, Inc.· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

  NCT06806852· Phase 1· Boehringer Ingelheim· Source

• Not yet recruiting

  An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

  NCT06855849· Phase 2· Yonsei University· Source

• Recruiting

  A Multicenter Study of RUS NE

  NCT06868186· Hutom Corp· Source

Showing 50 of 151.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Liver and biliary tract cancer13 recruiting
• Colorectal cancer8 recruiting
• Gastric and oesophageal cancer7 recruiting
• Ovarian cancer7 recruiting
• Childhood cancers6 recruiting
• Atrial fibrillation5 recruiting
• Head and neck cancer5 recruiting
• High blood pressure5 recruiting
• Type 2 diabetes5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Heart failure4 recruiting
• Chronic kidney disease3 recruiting
• Endometrial cancer3 recruiting
• Kidney cancer3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Alzheimer disease2 recruiting
• Bladder cancer2 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Neuroendocrine tumours2 recruiting
• Osteoarthritis2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• Bronchiectasis1 recruiting
• Cerebral palsy1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• Hepatitis B1 recruiting
• IgA nephropathy1 recruiting
• Liver cirrhosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Peripheral artery disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Spinal muscular atrophy1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma

  NCT07043348· Seoul National University Hospital· Source

• Completed

  Feasibility of RUS Lung in MITS

  NCT06952894· Hutom Corp· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

  NCT06747936· Phase 3· Addpharma Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

  NCT07028697· Phase 3· Nxera Pharma Korea Co., Ltd.· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

  NCT06329141· Phase 2· Glaceum· Source

• Terminated

  A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

  NCT06186076· Phase 1/2· Therapex Co., Ltd· Source

• Completed

  DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

  NCT06406439· G2e Co., Ltd· Source

• Completed

  A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

  NCT06024408· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  Endovascular Coiling Using Target Tetra® Coils for Small Intracranial Aneurysm

  NCT06064435· Yonsei University· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

  NCT06144788· Phase 2· Jeil Pharmaceutical Co., Ltd.· Source

• Terminated

  GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

  NCT05998447· Phase 2· Genome & Company· Source

• Completed

  Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia

  NCT06339853· Yonsei University· Source

• Completed

  Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam

  NCT06563063· Yonsei University· Source

• Terminated

  A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

  NCT05660395· Phase 1· ADC Therapeutics S.A.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

  NCT05930028· Phase 3· Boryung Pharmaceutical Co., Ltd· Source

• Completed

  Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

  NCT05606094· Daiichi Sankyo Co., Ltd.· Source

• Completed

  A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

  NCT05804747· Daiichi Sankyo· Source

• Completed

  Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

  NCT05718375· Phase 2· Curacle Co., Ltd.· Source

• Completed

  Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

  NCT05630768· Phase 4· Dong-A ST Co., Ltd.· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

  NCT07564726· Phase 3· Celltrion Pharm, Inc.· Source

• Completed

  A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  NCT05133531· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· ALX Oncology Inc.· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· SK Life Science, Inc.· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER

  NCT04996303· Yonsei University· Source

• Completed

  Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

  NCT04903314· Phase 1· SK Life Science, Inc.· Source

• Completed

  FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

  NCT04768686· Phase 2· Hanmi Pharmaceutical Company Limited· Source

• Terminated

  Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

  NCT04820023· Phase 1/2· Bridge Biotherapeutics, Inc.· Source

• Completed

  Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

  NCT04484142· Phase 2· Daiichi Sankyo· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Syndax Pharmaceuticals· Source

• Completed

  Shared Decision Making for Choosing renAl Replacement Therapy in Chronic Kidney Disease Patients

  NCT04976166· Seoul National University Hospital· Source

• Completed

  KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  NCT04165083· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

  NCT04387461· Phase 2· CG Oncology, Inc.· Source

• Completed

  Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation

  NCT04583046· Yonsei University· Source

• Completed

  Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT04505436· Phase 2· Hanmi Pharmaceutical Company Limited· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

  NCT04799496· Takeda· Source

Showing 50 of 84.

Conditions

Diseases this institution publishes on or runs trials for.

• Ovarian cancer27 works · 11 trials
• Migraine20 works · 0 trials
• Psoriasis18 works · 1 trial
• Endometrial cancer13 works · 7 trials
• Idiopathic pulmonary fibrosis13 works · 4 trials
• High blood pressure11 works · 8 trials
• Brain aneurysm7 works · 2 trials
• Liver cirrhosis7 works · 1 trial
• Neuromyelitis optica (NMOSD)6 works · 0 trials